Bluestar Adisseo Company (SHA:600299)

Market Cap	26.79B
Revenue (ttm)	16.34B
Net Income (ttm)	1.39B
Shares Out	2.68B
EPS (ttm)	0.52
PE Ratio	19.18
Forward PE	17.78
Dividend	0.24 (2.40%)
Ex-Dividend Date	May 20, 2025

Volume	6,739,811
Average Volume	8,464,848
Open	9.94
Previous Close	9.91
Day's Range	9.93 - 10.07
52-Week Range	9.20 - 12.85
Beta	0.64
RSI	53.27
Earnings Date	Jul 29, 2025

About Verve Therapeutics

Bluestar Adisseo Company engages in the research, development, production, and sale of feed additives for animal nutrition worldwide. The company offers Rhodimet, a methionine solution for animals, including Rhodimet AT88 and Rhodimet NP99; Smartamine and MetaSmart for proper balance of amino acid; AdiSodium, a feed material for monogastrics and ruminants; Microvit, a vitamin additives in animal nutrition; Krave AP stimulate appetite and feed intake during lactation; Optisweet, a feed sweetener to stimulate early feed intake; Gusti Plus improve...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1939
• Employees: 2,929
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600299

Financial Performance

In 2024, Bluestar Adisseo Company's revenue was 15.53 billion, an increase of 17.83% compared to the previous year's 13.18 billion. Earnings were 1.20 billion, an increase of 2208.66%.